These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27537400)

  • 21. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
    Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
    Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
    Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
    Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
    Procopio G; Derosa L; Gernone A; Morelli F; Sava T; Zustovich F; De Giorgi U; Ferrari V; Sabbatini R; Gasparro D; Felici A; Burattini L; Calvani N; Lo Re G; Banna G; Pia Brizzi M; Rizzo M; Ciuffreda L; Iacovelli R; Ferraù F; Taibi E; Bracarda S; Porta C; Galligioni E; Contu A
    Future Oncol; 2014 Aug; 10(10):1741-50. PubMed ID: 24641206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry.
    Kubackova K; Bortlicek Z; Pavlik T; Melichar B; Linke Z; Pokorna P; Vyzula R; Prausova J; Buchler T;
    Target Oncol; 2015 Sep; 10(3):385-92. PubMed ID: 25304882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
    Miyake H; Miyazaki A; Imai S; Harada K; Fujisawa M
    Target Oncol; 2016 Apr; 11(2):175-82. PubMed ID: 26341668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study.
    Zhang HL; Qin XJ; Wang HK; Gu WJ; Ma CG; Shi GH; Zhou LP; Ye DW
    Oncotarget; 2015 Nov; 6(34):36870-83. PubMed ID: 26472104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
    Flörcken A; Takvorian A; Van Lessen A; Singh A; Hopfenmüller W; Dörken B; Pezzutto A; Westermann J
    Anticancer Drugs; 2012 Mar; 23(3):298-302. PubMed ID: 22156795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
    Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
    Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma.
    Komai Y; Saito K; Sakai K; Morimoto S
    BJU Int; 2007 Jan; 99(1):77-80. PubMed ID: 16956357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study.
    Kim SH; Kim S; Nam BH; Lee SE; Kim CS; Seo IY; Kim TN; Hong SH; Kwon TG; Seo SI; Joo KJ; Song K; Kwak C; Chung J
    Biomed Res Int; 2017; 2017():9215930. PubMed ID: 28271073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
    Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
    Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
    [No Abstract]   [Full Text] [Related]  

  • 33. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
    Furuya N; Kamai T; Shirataki H; Yanai Y; Fukuda T; Mizuno T; Nakamura F; Kambara T; Nakanishi K; Abe H; Yoshida K
    Cancer Immunol Immunother; 2011 Jun; 60(6):793-808. PubMed ID: 21350947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.
    Hatiboglu G; Hohenfellner M; Arslan A; Hadaschik B; Teber D; Radtke JP; Hallscheidt P; Tolstov Y; Roth W; Grüllich C; Huesing J; Duensing S; Pahernik S
    Langenbecks Arch Surg; 2017 Jun; 402(4):637-644. PubMed ID: 28012035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
    Araki H; Tsuzuki T; Kimura T; Tanaka K; Yamada S; Sassa N; Yoshino Y; Hattori R; Gotoh M
    Am J Clin Pathol; 2015 Apr; 143(4):492-9. PubMed ID: 25780000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
    J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
    J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.